Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Lizzie Aby, MD Profile picture
Lizzie Aby, MD
@LizzieAbyMD
Transplant Hepatology Fellow @UMN_GIHEP| @LiverFellow co-founder | AASLD Emerging Liver Scholar alum| Former UCLA Chief Resident |@pomonacollege alum|Tweets=own
Jun 25, 2020 • 13 tweets • 7 min read
For #GIJournalClub – we will discussing the @NEJM article:
Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al.
Expert opinion: @SeragHashem
Moderators: @AtoosaRabiee @jturnesv

nejm.org/doi/full/10.10…

#livertwitter #GIJC #hpbcsm Background:
- Sorafenib in 2008: improved OS + longer time to radiologic progression vs placebo
nejm.org/doi/full/10.10…

Single agent PD-L1 inhibitor w/o improved OS
- Nivoumab vs sorafenib: No statistically significant improvement in OS w/nivolumab
sciencedirect.com/science/articl…
Jun 25, 2020 • 15 tweets • 9 min read
For #GIJournalClub – we will discussing the @NEJM article:
Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al.
Expert opinion: @SeragHashem
Moderators: @AtoosaRabiee @jturnesv

nejm.org/doi/full/10.10…

#livertwitter #GIJC #hpbcsm Background:
✅ Sorafenib in 2008: improved OS + longer time to radiologic progression vs placebo
nejm.org/doi/full/10.10…

Single agent PD-L1 inhibitor w/o improved OS
✅ Nivoumab vs sorafenib: No statistically significant improvement in OS w/nivolumab
sciencedirect.com/science/articl…
May 28, 2020 • 4 tweets • 4 min read
Grateful to @DougSimonetto from @MayoClinicGIHep for talking to @UMN_GI about the recent the @AmCollegeGastro guidelines on Disorders of Hepatic and Mesenteric Circulation (as a part of our @AASLDtweets ELS project!)

pubmed.ncbi.nlm.nih.gov/31895720/ ⭐️ Coagulopthy of liver disease is a delicate balance ⚖️
☑️INR is 🚫 a useful marker to asses clotting & bleeding risk
☑️ For high risk procedures, consider TPO agonist if plt < 50k & not emergent (takes 5-7 days). beware in history of PVT
☑️Consider viscoelastic tests
May 3, 2020 • 9 tweets • 29 min read
@ScopingSundays @HassaanZiaMD @AtoosaRabiee @BilalMohammadMD @vaibhav_manu @AhmadBazarbashi @rmulkimd @RobertoSimonsMD @DrMalSimons @KellyHathornMD @NnekaUfereMD @JacquelineChuMD @TedWJamesMD 57 y/o M w/cirrhosis p/w melenic stools & hematemesis. EGD 1 yr ago w/small EV. BP 90/50, HR 110 & 96% on RA. Clammy extremities. Abdomen non tender. No ascites or edema. Pt has another episode of hematemesis. Hgb 8, Plt 165k, INR 1.8, Tb 2.1, Cr 1.4 & Na 134.
What is your plan? @ScopingSundays @HassaanZiaMD @AtoosaRabiee @BilalMohammadMD @vaibhav_manu @AhmadBazarbashi @rmulkimd @RobertoSimonsMD @DrMalSimons @KellyHathornMD @NnekaUfereMD @JacquelineChuMD @TedWJamesMD To start out #ScopingSundays - we will quickly review the pre-endoscopic management of bleeding esophageal varices!
#livertwitter #GITwitter #tweetorial